Why Medtech Giants Are Quietly Paying Up for AI Diagnostics

Rhea-AI Summary

Danaher (NYSE: DHR), Medtronic (NYSE: MDT), DexCom (NASDAQ: DXCM), Profound Medical (NASDAQ: PROF) and VentriPoint Diagnostics (TSXV: VPT / OTCPK: VPTDF) are highlighted in a sector overview of rising AI diagnostics investment.

Key facts: Danaher reported Q1 2026 revenue of $6.0B (+3.5% YoY) and adjusted diluted EPS $2.06 (+9.5%), raised FY2026 EPS guide to $8.35–$8.55. Medtronic closed a $585M CathWorks deal. VentriPoint won a Gold Edison Award and holds US/Canada/Europe approvals for VMS+ 4.0.

AI-generated analysis. Not financial advice.

Positive

• Danaher Q1 revenue $6.0B (+3.5% YoY)
• Danaher adjusted EPS $2.06 (+9.5% YoY) and raised FY2026 EPS guidance to $8.35–$8.55
• Medtronic acquisition of CathWorks for $585M brings AI FFRangio into its portfolio
• VentriPoint awarded Gold Edison Award and holds regulatory approvals in US, Canada, Europe

Negative

• Cepheid respiratory season was lighter-than-typical, weighing on Danaher top-line in Q1
• Company-paid promotion disclosed, including ownership and ongoing paid advertising for VentriPoint, creating a conflict of interest risk for readers

News Market Reaction – VPTDF

+16.28%

1 alert

+16.28% News Effect

On the day this news was published, VPTDF gained 16.28%, reflecting a significant positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

AI imaging market size: $2.20 billion Market growth rate: 34.8% AI priority survey 2026-2027: 57% +5 more

8 metrics

AI imaging market size $2.20 billion Global AI in medical imaging market expected in 2026

Market growth rate 34.8% Growth rate for AI in medical imaging through 2033

AI priority survey 2026-2027 57% Hospital C-suite ranking AI clinical solutions as top tech priority

AI priority 2023 19% Hospital C-suite ranking AI clinical solutions as top priority in 2023

CathWorks acquisition value $585 million Medtronic acquisition of CathWorks, excluding potential earn-outs

ALL-RISE trial size more than 1,900 patients ALL-RISE randomized control trial for FFRangio System

Danaher Q1 2026 revenue $6.0 billion First quarter 2026 revenues, up 3.5% year-over-year

Danaher adjusted EPS $2.06 Q1 2026 non-GAAP adjusted diluted EPS, up 9.5% year-over-year

Market Reality Check

Price: $0.1050 Vol: Volume 23,270 is about in...

low vol

$0.1050 Last Close

Volume Volume 23,270 is about in line with recent activity, at 0.51x the 20-day average of 45,774. low

Technical Shares at 0.0774 are trading slightly below the 200-day MA of 0.08 and well under the 52-week high of 0.12.

Peers on Argus

Peers show mixed moves: names like PYNKF are up while others such as BTCY and LU...

Peers show mixed moves: names like PYNKF are up while others such as BTCY and LUDG are down, and no momentum scanner flags are present. This points to stock-specific rather than broad sector-driven trading.

Common Catalyst Some peers are also highlighting AI-enabled imaging and interventional platforms, but only 1 peer has news today, suggesting no unified sector catalyst.

Historical Context

2 past events · Latest: Feb 26 (Positive)

Pattern 2 events

Date	Event	Sentiment	Move	Catalyst
Feb 26	Investor interview feature	Positive	-7.0%	Interview touting VMS+ system, MRI wait reduction and hospital cost savings.
Nov 27	Strategy interview feature	Positive	-0.7%	CEO discussion on scaling ultrasound platform comparable to MRI imaging.

Pattern Detected

Recent promotional and interview-style coverage has coincided with negative next-day price reactions, suggesting a pattern of weak follow-through after positive narratives.

Recent Company History

Over the past several months, Ventripoint has been featured in investor-focused interviews emphasizing its VMS+ system as an MRI-comparable, bolt-on cardiac imaging solution that can cut cardiac MRI wait times by 4–5 days and potentially save hospitals up to $40,000 per scan in bed-day costs. Despite this upbeat positioning, the stock declined 7.05% after the February 2026 feature and 0.71% after the November 2025 interview. Today’s AI-focused article continues that theme of highlighting clinical and economic benefits to hospitals.

Market Pulse Summary

The stock surged +16.3% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +16.3% in the session following this news. A strong positive reaction aligns with the article’s focus on AI-enabled diagnostics, regulatory-cleared platforms, and real-world clinical evidence. Historically, VPTDF has seen price declines after upbeat interview-style coverage, so a large upside move would contrast with past divergence patterns. Investors would likely watch how commercial rollouts, hospital adoption, and execution on recent partnerships evolve, as well as whether enthusiasm fades once promotional attention normalizes.

Key Terms

ai diagnostics, real-world clinical evidence, randomized control trial, non-gaap, +4 more

8 terms

ai diagnostics technical

"There's a quiet bidding war underway for AI diagnostics, and the price keeps"

AI diagnostics are software tools that use machine learning to analyze medical information—such as images, lab results, or vital signs—to detect, classify or predict health conditions and support clinical decisions. For investors, they matter because successful AI diagnostics can make care faster and cheaper, expand access to testing, and create recurring revenue or partnership opportunities, while regulatory approval, clinical adoption and data quality determine their commercial value.

real-world clinical evidence medical

"The FDA has made it clear that real-world clinical evidence is now central"

Real-world clinical evidence consists of information about how medical treatments and interventions perform in everyday settings outside controlled research trials. For investors, it provides practical insights into a medication’s safety and effectiveness based on actual patient experiences, helping to assess the true value and potential success of healthcare products in real-life use.

randomized control trial medical

"ALL-RISE randomized control trial, which enrolled more than 1,900 patients"

A randomized controlled trial (RCT) is a carefully designed study where participants are randomly assigned to receive either a new treatment or a comparison (such as a placebo or existing therapy) so researchers can measure the treatment’s effect while minimizing bias. For investors, RCT results matter because they provide the most reliable evidence about whether a medical product works and is safe, much like a blind taste test revealing whether a new recipe truly outperforms the old one.

non-gaap financial

"with non-GAAP adjusted diluted EPS growing 9.5% to $2.06"

Non-GAAP refers to financial measures that companies use to show their earnings or performance without including certain expenses or income that are often added back to give a different picture. It matters because it can make a company's results look better or more favorable, but it may also hide important costs, so investors need to look at both GAAP (official rules) and non-GAAP numbers to get a full understanding.

adjusted diluted eps financial

"with non-GAAP adjusted diluted EPS growing 9.5% to $2.06"

Adjusted diluted EPS is a company’s profit per share after adding back or removing one-time items (like restructuring costs or gains) and dividing by the number of shares including potential shares from options and convertible securities. Investors use it as a cleaner view of ongoing earnings—like looking at a car’s regular fuel efficiency rather than a trip boosted by downhill coasting—to judge underlying performance and compare companies without temporary distortions.

core revenue growth financial

"and expects full year core revenue growth of 3% to 6%"

Core revenue growth measures how much a company's regular, recurring sales have increased after removing one-time events, unusual gains or currency swings so you see the business’s underlying performance. Investors care because it shows whether the company’s primary operations are actually expanding or contracting—like checking a car’s odometer for miles driven under normal conditions rather than counting a single long trip that would distort the picture.

continuous glucose monitoring medical

"role of continuous glucose monitoring across all diabetes types"

Continuous glucose monitoring is a system that tracks blood sugar levels in real-time throughout the day and night. It provides constant updates, similar to a car's dashboard showing speed and fuel level at all times. For investors, advancements in this technology can signal progress in health monitoring devices, which may influence the growth and valuation of companies in the healthcare sector.

randomized controlled trial medical

"CAPTAIN randomized controlled trial comparing TULSA against robotic"

A randomized controlled trial is a research method that tests the effects of a new idea or treatment by randomly dividing participants into two groups: one that receives the treatment and one that does not. This approach helps ensure that the results are fair and unbiased, providing clear evidence about whether the treatment actually works. Investors value such trials because they offer reliable information that can influence decision-making and reduce uncertainty.

AI-generated analysis. Not financial advice.

ISSUED ON BEHALF OF VENTRIPOINT DIAGNOSTICS LTD.

VANCOUVER, BC, April 29, 2026 /PRNewswire/ -- USANewsGroup.com News Commentary – There's a quiet bidding war underway for AI diagnostics, and the price keeps climbing. The global AI in medical imaging market is on track to hit $2.20 billion in 2026, with a 34.8% growth rate baked in through 2033^[1]. Q1 2026 healthcare M&A activity tells the same story: capital is rotating into AI-enabled platforms that already carry regulatory clearance, recurring revenue, and real clinical data behind them^[2]. That description fits a short list of names worth knowing right now: VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF), Medtronic (NYSE: MDT), Danaher (NYSE: DHR), Profound Medical (NASDAQ: PROF), and DexCom (NASDAQ: DXCM).

Hospitals are voting with their wallets too. A fresh C-suite survey shows 57% now rank AI clinical solutions as their top technology priority for 2026 to 2027, up from just 19% in 2023^[3]. The FDA has made it clear that real-world clinical evidence is now central to clearing AI software, which is exactly why institutional buyers are paying a clinical validation premium for platforms that already have multi-site data behind them^[4].

VentriPoint Diagnostics (TSXV: VPT) (OTCPK: VPTDF) just picked up a Gold Medal at the 2026 Edison Awards for its AI-powered cardiac imaging platform, VMS+™ 4.0. The Edison Awards are widely considered one of the most prestigious innovation prizes in the world, often called "the Oscars of Innovation," and past Gold winners include Abbott, Medtronic, and Boston Scientific. For a small-cap medtech company out of Toronto, that is serious company to keep.

The technology behind the award takes a standard 2D ultrasound scan and converts it into a detailed 3D model of the heart. The company says the results are comparable to a cardiac MRI, but without the million-dollar machine or the months-long wait list. VMS+™ 4.0 is already deployed in hospitals across the United States, Canada, the United Kingdom, and Europe, which is a key reason the Edison judges took notice. Their evaluation process places heavy weight on technologies that have moved past the pilot stage and into real clinical use.

That momentum is showing up in VentriPoint's commercial pipeline. The company recently announced a collaboration with the Health Division of the Montecristo Group to roll out VMS+™ across Costa Rica's public and private hospital networks. The Montecristo Group's Hospital Metropolitano also has an existing relationship with Sanford Health, one of the largest healthcare systems in the United States. VentriPoint also recently partnered with First Light Health, an Indigenous-owned medical services company, to bring cardiac diagnostics to Indigenous and remote communities across Canada through a hub-and-spoke model. That program builds on an earlier partnership with the Nisga'a Valley Health Authority in northern BC. South of the border, the company signed a commercial agreement with LG Consulting Solutions targeting cardiac centres in Northern California.

"Being awarded Gold affirms that VMS™ 4.0 has reached that threshold, and reinforces our belief that our platform has significant room to grow as adoption accelerates and new applications emerge," said Hugh MacNaught, CEO of VentriPoint.

VentriPoint holds regulatory approvals in the United States, Canada, and Europe. Its VMS+™ platform is vendor-agnostic, meaning it works with ultrasound equipment from any manufacturer, and is built on more than a decade of proprietary Knowledge Based Reconstruction technology. The core value proposition is MRI-grade cardiac imaging at a fraction of the cost, deployable anywhere a standard ultrasound machine already sits. With a growing global footprint, a validated technology platform, and independent recognition from one of the world's top innovation bodies, VentriPoint is positioning itself as a name to watch in precision health.

CONTINUED… Read this and more news for VentriPoint Diagnostics at:  https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint

Other industry developments and happenings in the market include:

Medtronic (NYSE: MDT) completed its acquisition of CathWorks, a privately held medical device company focused on coronary artery disease diagnosis and treatment, for $585 million with potential additional earn-out payments. The deal follows a 2022 co-promotion agreement and brings the CathWorks FFRangio System, an AI-powered, drug-free, wire-free coronary assessment platform, into Medtronic's interventional cardiology portfolio.

"The acquisition of CathWorks significantly enhances Medtronic's interventional cardiology portfolio with an innovative system that empowers physicians with data-driven insights for the diagnosis and treatment of coronary artery disease," said Jason Weidman, senior vice president and president of the Coronary & Renal Denervation business, part of the Cardiovascular Portfolio at Medtronic. "Through our global footprint, welcoming CathWorks to Medtronic will expand access to the transformative FFRangio technology for our customers and their patients worldwide."

The FFRangio System recently demonstrated non-inferiority to wire-based physiology in the ALL-RISE randomized control trial, which enrolled more than 1,900 patients across 59 sites globally. The acquisition is expected to be immaterial to Medtronic's fiscal year 2027 earnings and neutral to accretive thereafter, continuing the company's strategy of targeted tuck-in acquisitions to strengthen its core franchises.

Danaher (NYSE: DHR) reported first quarter 2026 results showing revenues of $6.0 billion, up 3.5% year-over-year, with non-GAAP adjusted diluted EPS growing 9.5% to $2.06. Operating cash flow reached $1.3 billion, supported by strength in Bioprocessing and better-than-expected Life Sciences performance.

"Our team executed well in the first quarter, which enabled us to accelerate innovation, drive productivity gains, and deliver nearly 10% adjusted EPS growth," said Rainer M. Blair, President and CEO of Danaher. "On the top line, we continued on a steady recovery path with strength in Bioprocessing and better-than-expected performance in Life Sciences largely offsetting the impact of a lighter-than-typical Q1 respiratory season at Cepheid."

Danaher raised its full year 2026 adjusted diluted EPS guidance to $8.35 to $8.55, up from prior guidance of $8.35 to $8.50, and expects full year core revenue growth of 3% to 6%. The company also announced its intention to acquire Masimo Corporation, a provider of pulse oximetry and patient monitoring solutions, citing opportunities to enhance performance through the Danaher Business System and its global scale.

Profound Medical (NASDAQ: PROF) is highlighting its TULSA-PRO system across seven presentations at the 2026 Society of Interventional Radiology Annual Scientific Meeting in Toronto, April 11-15. The commercial-stage medical device company's AI-powered, MRI-guided TULSA Procedure treats prostate cancer and benign prostatic hyperplasia without incisions, eliminating procedural blood loss and overnight hospital stays while minimizing side effects such as urinary incontinence and erectile dysfunction.

"Our significant presence at SIR 2026 comes at an opportune time as leading iMRI procedures, including MRI-guided biopsy and TULSA, are poised to transform how unmet medical needs across the prostate disease spectrum are being addressed," said Arun Menawat, CEO and Chairman of Profound Medical. "Awareness and acceptance of the TULSA Procedure's strong clinical profile, as well as its potential to become the next mainstream treatment modality for most men with prostate disease, is growing."

Presentations will feature data from the Level 1 post-market CAPTAIN randomized controlled trial comparing TULSA against robotic prostatectomy for intermediate-risk prostate cancer. Profound Medical also commercializes Sonalleve, an MRI-guided therapy addressing bone metastases pain palliation, uterine fibroids, and adenomyosis, with its technologies approved across major global markets including the United States, Europe, and Canada.

DexCom (NASDAQ: DXCM) is showcasing new clinical evidence at the 19th annual Advanced Technologies and Treatments for Diabetes Conference in Barcelona, reinforcing the role of continuous glucose monitoring across all diabetes types. A multi-center primary care registry study showed that after one year of Dexcom G7 use, people with Type 2 diabetes not on insulin therapy saw significant improvements in A1C and weight management, while claims data linked Dexcom CGM initiation to meaningful reductions in DKA-related hospitalizations and emergency room visits in both children and adults with Type 1 diabetes.

"There is no better global stage than ATTD to showcase how we're shaping the future of glucose biosensing around the world," said Jake Leach, president and chief executive officer at DexCom. "The data presented at ATTD reinforces the need for Dexcom CGM to become the standard of care for all people with Type 2 diabetes, including those not using insulin."

Beyond the clinical data, DexCom is presenting its near- and long-term product roadmap, including upcoming features for Dexcom G7, Dexcom G7 15 Day, and Stelo, its health and wellness offering. The company recently launched Dexcom G7 15 Day in the U.S. and continues expanding its Dexcom Academy HCP education platform across Europe and the Middle East.

Further Reading: https://usanewsgroup.com/2025/11/21/the-mri-grade-disruption-hiding-in-plain-sight-why-the-smart-money-is-watching-ventripoint

CONTACT:
USA NEWS GROUP
info@usanewsgroup.com
(604) 265-2873

DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. USA News Group is a wholly-owned subsidiary of Market IQ Media Group, Inc. (MIQ). This article is being distributed for Baystreet.ca media Corp, who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Ventripoint Diagnostics Ltd. advertising or digital media, but the owner/operators of MIQ also co-owns Baystreet.ca Media Corp. (BAY) There may also be 3rd parties who may have shares of Ventripoint Diagnostics Ltd. and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ/BAY own shares of Ventripoint Diagnostics Ltd and reserve the right to buy and sell, and will buy and sell shares of Ventripoint Diagnostics Ltd. at any time without any further notice commencing immediately and ongoing. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ on behalf of BAY has been approved by Ventripoint Diagnostics Ltd.; this is a paid advertisement, we currently own shares of Ventripoint Diagnostics Ltd. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.

SOURCES:

1. https://www.coherentmarketinsights.com/industry-reports/ai-in-medical-imaging-market 
2. https://www.sikich.com/insight/q1-2026-healthcare-ma-market-update/ 
3. https://hitconsultant.net/2026/03/24/sage-growth-partners-health-it-purchasing-forecast-2026-2027-ai-roi/ 
4. https://www.fda.gov/news-events/fda-voices/real-world-evidence-advancing-regulatory-decision-making-medical-devices 

Logo - https://mma.prnewswire.com/media/2838876/5919929/USA_News_Group_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/why-medtech-giants-are-quietly-paying-up-for-ai-diagnostics-302757277.html

FAQ

What did Danaher (DHR) report for Q1 2026 revenue and EPS?

Danaher reported Q1 2026 revenue of $6.0 billion and adjusted diluted EPS of $2.06. According to Danaher, revenue rose 3.5% year-over-year and adjusted EPS grew 9.5%, with operating cash flow of $1.3 billion.

How much did Medtronic (MDT) pay for CathWorks and what did it acquire?

Medtronic completed a $585 million acquisition of CathWorks to add the AI-powered FFRangio coronary assessment system. According to Medtronic, the deal integrates FFRangio into its interventional cardiology portfolio and follows a prior co-promotion agreement.

What recognition and approvals does VentriPoint (VPT / VPTDF) claim for VMS+ 4.0?

VentriPoint won a Gold Edison Award for VMS+ 4.0 and holds regulatory approvals in the United States, Canada, and Europe. According to VentriPoint, VMS+ converts 2D ultrasound to MRI-grade 3D cardiac models and is vendor-agnostic.

How might Danaher's announced Masimo acquisition affect DHR shareholders?

Danaher announced its intention to acquire Masimo, citing scale and Danaher Business System benefits. According to Danaher, the transaction is intended to enhance performance, though integration outcomes and timing were not quantified in the announcement.

What conflict of interest was disclosed in the press coverage mentioning VentriPoint (VPT)?

The publication discloses it is a paid advertisement and that owner/operators own shares of VentriPoint and may trade them. According to the disclosure, this compensation and ownership constitute a conflict of interest for readers evaluating the coverage.